Filtered By:
Drug: Meridia
Management: European Medicines Agency (EMA)

This page shows you your search results in order of date.

Order by Relevance | Date

Total 2 results found since Jan 2013.

Evolution of Pharmacological Obesity Treatments: Focus on Adverse Side‐Effect Profiles
ABSTRACT Pharmacotherapy directed toward reducing body weight may provide benefits for both curbing obesity and lowering the risk of obesity‐associated co‐morbidities. However, many weight loss medications have been withdrawn from the market due to serious adverse effects. Examples include pulmonary hypertension (aminorex), cardiovascular toxicity, e.g. flenfluramine‐induced valvopathy, stroke (phenylpropanolamine), excess non‐fatal cardiovascular events (sibutramine), and neuro‐psychiatric issues (rimonabant ‐ approved in Europe, but not in the US). This negative experience has helped mold the current drug dev...
Source: Diabetes, Obesity and Metabolism - March 1, 2016 Category: Endocrinology Authors: Andrew J. Krentz, Ken Fujioka, Marcus Hompesch Tags: REVIEW ARTICLE Source Type: research

A safe, effective diet pill - the elusive holy grail
Trade in illegal, ineffective drugs flourishes as pharmaceutical industry repeatedly fails to produce successful pillAttempts to invent a safe and effective diet pill have foundered time and again, allowing the internet trade in illegal and ineffective herbal supplements and dangerous drugs, such as DNP, to flourish.A successful diet pill could make billions for the pharmaceutical industry, but efforts to date have ended in disaster, with patients harmed, drugs banned and massive compensation paid out.Fen-phen, an appetite suppressant, was the most spectacular failure. It was withdrawn in the US in 1997 after causing wides...
Source: Guardian Unlimited Science - January 14, 2014 Category: Science Authors: Sarah Boseley Tags: The Guardian Diets and dieting Drugs trade Healthcare industry World news Pharmaceuticals industry & wellbeing Health policy Society Politics UK news Life and style Public services policy Business Science Source Type: news